Clinical characteristics of 48 allogeneic HSCT patients
| Characteristic . | −cGVHD* (N = 28) . | +cGVHD (N = 20) . | P value . |
|---|---|---|---|
| Median age, year (range) | 58 (21-73) | 51 (28-67) | .39 |
| Sex, no. (%) of females | 8 (40) | 14 (50) | .57 |
| Median time after transplant, mo (range) | 23 (10-110) | 25 (12-116) | .96 |
| Conditioning regimen (%) | |||
| Myeloablative | 15 (54) | 6 (30) | .14 |
| Nonmyeloablative | 13 (46) | 14 (70) | |
| Source of graft (%) | |||
| Peripheral blood | 26 (93) | 18 (90) | 1.00 |
| Bone marrow | 2 (7) | 2 (10) | |
| HLA matching (%) | |||
| Matched, unrelated | 8 (29) | 10 (50) | .15 |
| Matched, related | 18 (64) | 7 (35) | |
| Mismatched | 2 (7) | 3 (15) | |
| Immunosuppressive treatment (%)† | |||
| Prednisone ≤30 mg (2.5-30 mg)/day | 4 (14) | 12 (60) | .002 |
| MMF | 0 (0) | 1 (5) | .42 |
| Tacrolimus | 5 (18) | 6 (30) | .49 |
| Rapamycin | 3 (15) | 0 (0) | .07 |
| ATG | 5 (18) | 4 (20) | 1.00 |
| Alemtuzumab | 2 (7) | 0 (0) | .50 |
| aGVHD | |||
| Grade I, no. (%) | 7 (25) | 8 (40) | .74 |
| Grade II, no. (%) | 2 (7) | 1 (5) | |
| Grade III, no. (%) | 1 (4) | 0 (0) | |
| Disease (%) | |||
| AML / AML from MDS | 14 (50) | 9 (45) | |
| ALL | 2 (7) | 2 (10) | |
| CML | 1 (4) | 0 (0) | |
| CLL | 2 (7) | 4 (20) | .81 |
| MDS | 4 (14) | 2 (10) | |
| NHL | 1 (4) | 2 (10) | |
| MM | 1 (4) | 0 (0) | |
| AA | 2 (7) | 0 (0) | |
| HL | 1 (4) | 1 (5) |
| Characteristic . | −cGVHD* (N = 28) . | +cGVHD (N = 20) . | P value . |
|---|---|---|---|
| Median age, year (range) | 58 (21-73) | 51 (28-67) | .39 |
| Sex, no. (%) of females | 8 (40) | 14 (50) | .57 |
| Median time after transplant, mo (range) | 23 (10-110) | 25 (12-116) | .96 |
| Conditioning regimen (%) | |||
| Myeloablative | 15 (54) | 6 (30) | .14 |
| Nonmyeloablative | 13 (46) | 14 (70) | |
| Source of graft (%) | |||
| Peripheral blood | 26 (93) | 18 (90) | 1.00 |
| Bone marrow | 2 (7) | 2 (10) | |
| HLA matching (%) | |||
| Matched, unrelated | 8 (29) | 10 (50) | .15 |
| Matched, related | 18 (64) | 7 (35) | |
| Mismatched | 2 (7) | 3 (15) | |
| Immunosuppressive treatment (%)† | |||
| Prednisone ≤30 mg (2.5-30 mg)/day | 4 (14) | 12 (60) | .002 |
| MMF | 0 (0) | 1 (5) | .42 |
| Tacrolimus | 5 (18) | 6 (30) | .49 |
| Rapamycin | 3 (15) | 0 (0) | .07 |
| ATG | 5 (18) | 4 (20) | 1.00 |
| Alemtuzumab | 2 (7) | 0 (0) | .50 |
| aGVHD | |||
| Grade I, no. (%) | 7 (25) | 8 (40) | .74 |
| Grade II, no. (%) | 2 (7) | 1 (5) | |
| Grade III, no. (%) | 1 (4) | 0 (0) | |
| Disease (%) | |||
| AML / AML from MDS | 14 (50) | 9 (45) | |
| ALL | 2 (7) | 2 (10) | |
| CML | 1 (4) | 0 (0) | |
| CLL | 2 (7) | 4 (20) | .81 |
| MDS | 4 (14) | 2 (10) | |
| NHL | 1 (4) | 2 (10) | |
| MM | 1 (4) | 0 (0) | |
| AA | 2 (7) | 0 (0) | |
| HL | 1 (4) | 1 (5) |
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; NHL, non-Hodgkin lymphoma.
Included 22 patients who had never developed cGVHD and 6 patients with resolved or inactive cGVHD on date of sample collection.
On date of sample collection.